Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms.
- Author:
Ming LIU
1
;
Jianye WANG
2
;
Yong YANG
3
;
Ruihua AN
4
;
Jianguo WEN
5
;
Zhichen GUAN
6
;
Shaobin ZHENG
7
;
Dongwen WANG
8
;
Bo SONG
9
;
Limin LIAO
10
;
Hongqian GUO
11
;
Jiaquan XIAO
12
;
Yinghao SUN
13
;
Zhoujun SHEN
14
;
Chuize KONG
15
;
Dalin HE
16
;
Yiran HUANG
17
;
Xiaofeng WANG
18
;
Xu ZHANG
19
;
Hanzhong LI
20
;
Jian HUANG
21
;
Xiaokun ZHAO
22
;
Puqing ZENG
23
;
Xishuang SONG
24
;
Zhangqun YE
25
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; therapeutic use; Prospective Studies; Quality of Life; Quinuclidines; therapeutic use; Solifenacin Succinate; Tetrahydroisoquinolines; therapeutic use; Treatment Outcome; Urinary Bladder, Overactive; drug therapy
- From: Chinese Medical Journal 2014;127(2):261-265
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDOveractive bladder (OAB) is a series of symptoms with high prevalence in elderly people. This study was conducted using the overactive bladder symptom score (OABSS) to evaluate the efficacy of solifenacin succinate for the treatment of OAB.
METHODSThis was a prospective, multicenter, single-arm, 12-week study that enrolled 241 OAB patients. The patients received 5-10 mg/day solifenacin. Changes in OABSS, symptoms from voiding diary, perception of bladder condition (PPBC) score, international prostate symptom score (IPSS) and quality of life (QOL) were evaluated at weeks 0, 4, and 12. The relationship between OABSS and PPBC score or parameters of voiding diary was also evaluated.
RESULTSAt baseline, the mean OABSS for all patients was 9.41 ± 2.40, and was reduced significantly at week 12 (-3.76 points; 61.21%, P < 0.0001). The OABSS subscore, PPBC score, IPSS, and QOL were also significantly reduced during the study (P < 0.0001). The overall incidence of adverse events was 19.91% (44 cases). The gastrointestinal system was the most commonly affected (11.31%). Around 5.88% of the cases had adverse events related to the genitourinary system. There was a strong correlation between OABSS and urinary symptoms that was recorded in the 3-day voiding dairy.
CONCLUSIONSWe showed that solifenacin was clinically effective for relieving OAB symptoms, considering the balance between efficacy, patients' well-being, and tolerability. OABSS integrates four OAB symptoms into a single score and can be a useful tool for research and clinical practice.